Drug, across the briefings
Lestaurtinib across 8 cancers
Lestaurtinib appears in 8 of the briefings; no FDA label names any of them.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Acute lymphoblastic leukemia | approved on JAK2 | 1 | 0 | |
| Acute myeloid leukemia | approved on FLT3 | 3 | 0 | |
| Chronic myeloid leukemia | approved on JAK2 | — | — | |
| Colorectal cancer | approved on NTRK1 | — | — | |
| Hodgkin lymphoma | approved on JAK2 | — | — | |
| Lung cancer | approved on RET, NTRK1 | — | — | |
| Soft tissue sarcoma | approved on NTRK1 | — | — | |
| Thyroid cancer | approved on RET, NTRK1 | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.